Posted by Michael Wonder on 11 Jun 2018
Rheumatoid arthritis: few indications of the benefits of certain biologics over others
6 June 2018 - Still no long-term studies and little direct comparisons of biologics/first-time also first-line therapy examined.
For the second time, the IQWiG presents an extensive benefit assessment for a substance class in rheumatoid therapy, the so-called biologics. While in 2013 only the use in the second-line therapy was examined, this time it is also about the first line. In addition, the biologics should be compared with each other.
The result of the now published preliminary report: for three of the therapy situations differentiated in the report, indications for advantages or disadvantages of individual active substances compared to other biologicals can be determined - however, only in a few patient-relevant outcomes.
